Human lipoprotein lipase (LPL) deficiency causes profound hypertriglyceridemia and life-threatening pancreatitis. We recently developed an adult murine model for LPL deficiency: LPL؊/؊ mice display grossly elevated plasma triglyceride (TG) levels (Ͼ200-fold) and very low high-density lipoprotein cholesterol (HDL-C Ͻ 10% of normal). We used this animal model to test the efficacy of adeno-associated virus-mediated expression of hLPL S447X (AAV1-LPL S447X ) in muscle for the treatment of LPL deficiency. Intramuscular administration of AAV1-LPL S447X resulted in dose-dependent expression of hLPL protein and LPL activity (up to 33% of normal murine levels) in postheparin plasma. Remarkably, visible hyperlipidemia was resolved within 1 week; plasma TG was reduced to near-normal levels (from 99.0 to 1.8 mmol/L), and plasma HDL-C was increased 6-fold (from 0.2 to 1.1 mmol/L). At 8 months after administration of AAV1-LPL S447X , an intravenous lipid challenge showed efficient, near-normal clearance of plasma TG. Histologic analyses of injected muscle further indicated that abnormal muscle morphology observed in LPL؊/؊ mice was reversed after treatment. Expression of therapeutic levels of LPL S447X , and the subsequent beneficial effect on plasma lipid levels, has lasted for more than 1 year. We therefore conclude that AAV1-mediated transfer of LPL S447X into murine skeletal muscle results in long-term near-correction of dyslipidemia associated with LPL deficiency.
INTRODUCTION L
IPOPROTEIN LIPASE (LPL) has a central role in lipoprotein metabolism and energy homeostasis. Bound to proteoglycans on the luminal side of capillaries and arteries, and particularly abundant in muscle and adipose tissue, LPL catalyses the rate-limiting step for the hydrolysis of triglycerides (TG) in chy-lomicrons (CM) and large very low-density lipoproteins, controlling free fatty acid (FFA) uptake in adjacent tissues (Goldberg, 1996) . LPL activity is essential for the maturation of HDL particles (Bijvoet et al., 1996; Strauss et al., 2001) . LPL also acts as a ligand or molecular bridge between lipoproteins and proteoglycans or receptors, enhancing receptor-mediated uptake of various lipoproteins (Beisiegel et al., 1991; Eisenberg et al., 1992; Saxena et al., 1992; Williams et al., 1992; Merkel et al., 2002) , lipids, and lipophilic vitamins (Williams et al., 1992; Sattler et al., 1996) .
Human LPL deficiency (type I hyperlipoproteinemia) is a rare, autosomal recessive trait characterized by profound hypertriglyceridemia associated with intense chronic abdominal pain, hepatosplenomegaly, eruptive xanthomas, lipemia retinalis, dyspnea, monoparesthesias or polyparesthesias, and memory loss (Brunzell and Deeb, 2001) . Prolonged plasma TG elevation can cause recurrent episodes of potentially lethal pancreatitis, chronic pancreatic insufficiency, and diabetes mellitus. LPL deficiency is refractory to lipid-lowering drugs, and enzyme replacement therapy is ineffective because of the short half-life of exogenous LPL in plasma . Patients must adhere to a strict diet, restricting dietary fat intake to less than 15% of calories (Brunzell and Deeb, 2001 ). Nevertheless, serum TG levels may remain elevated, with disease symptoms persisting.
Adenoviral vector (Ad)-mediated gene transfer of LPL to mouse and cat models of LPL deficiency have established the first proof-of-principle demonstrating that LPL gene delivery can ameliorate the severe dyslipidemia associated with LPL deficiency (Excoffon et al., 1997; Liu et al., 2000) . However, this therapy was curtailed by transient expression of LPL resulting from inherent limitations of the adenovirus vector, and the formation of antibodies against human LPL .
Significant advances have been made in the development of gene therapy vectors for long-term transgene expression, as exemplified by the successful correction of hemophilia B in mice and dogs using adeno-associated vector (AAV)-mediated gene transfer (Chao et al., 1999; Wang et al., 1999; Herzog et al., 2001) . Several early-phase human clinical trials using AAV have demonstrated safety (Kay et al., 2000; Wagner et al., 2002; Manno et al., 2003) . There are at least eight different natural serotypes of AAV with varied tropism and transduction efficiencies (Gao et al., 2002) . Most widely used is AAV serotype 2 (AAV2); however, several groups have demonstrated that AAV1, AAV5, and AAV7 transduce muscle cells more efficiently (Xiao et al., 1999; Chao et al., 2000 Chao et al., , 2001 Arruda et al., 2004) . This is of interest, because muscle represents one of the natural sites of LPL expression, and because it is a large and accessible tissue.
We recently developed a murine model for LPL deficiency. While homozygous LPL deficiency in mice results in neonatal death, transient adenoviral expression of LPL S447X at birth provides efficient rescue to adulthood. The LPL S447X variant, present in 18.8-25.4% of the general population (Gagne et al., 1999; McGladdery et al., 2001) , represents a gain-of-function mutation that is associated with significant benefits, including decreased plasma TG and increased high-density lipoprotein cholesterol (HDL-C; Groenemeijer et al., 1997; Wittrup et al., 1999; Garenc et al., 2000; Chen et al., 2001; Clee et al., 2001) . Muscle expression of LPL S447X results in improved albeit transient disease correction over wild-type LPL (LPL WT ) after adenoviral gene transfer in adult LPLϪ/Ϫ mice (Ross et al., 2004) . Similar to human LPL deficiency, adult LPLϪ/Ϫ mice display grossly elevated plasma TG levels (Ͼ 200-fold) and very low HDL-C (Ͻ10% of normal). In the current study, we used LPLϪ/Ϫ mice to test the efficacy of AAV1-mediated expression of LPL S447X in skeletal muscle.
Our results show long-term expression of therapeutic levels of LPL and concomitant correction of dyslipidemia in LPLϪ/Ϫ mice, following a single intramuscular administration of AAV1-LPL S447X . This study describes a further step toward development of gene therapy for the treatment of human LPL deficiency.
MATERIALS AND METHODS

Preparation of AAV vectors
rAAV vectors were produced by calcium phosphate-mediated cotransfection of AAV1 helper plasmid pDP1, a derivative of pDG (Grimm et al., 2003) and vector plasmid (pVD5 or pTRCGW) in 293 cells (Hermens et al., 1999) . pDP1 was used to produce recombinant (r)AAV with AAV2 inverted terminal repeats (ITRs), pseudotyped with AAV1 capsids. The bovine growth hormone polyadenylation sequence (bGH polyA) and woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) were added to enhance transcription (Donello et al., 1998) . Vector plasmid pTRCGW was used to produce AAV virus expressing GFP. pTRCGW is composed of the vector cassette; 5Ј AAV-ITR-CMV promoter-GFP-WPREbGH polyA-AAV-ITR 3Ј inserted in plasmid vector pBS (ϩ). A vector plasmid for the production of AAV virus expressing the human LPL S447X protein (AAV1-LPL S447X ) was constructed by exchanging the GFP gene of pTRCGW for the 1.6 kb LPL S447X gene, resulting in pVD5. rAAV was purified as described (Zolotukhin et al., 1999) and further concentration was achieved using tangential flow filtration. Viral titer in terms of genome copies per milliliter (gc/ml) was determined by quantitative polymerase chain reaction (PCR).
Animals
LPLϪ/Ϫ mice were obtained by breeding LPLϩ/Ϫ female mice (kindly provided by Dr. Clay Semenkovich, Washington University, St. Louis, MO) with LPLϩ/Ϫ or Ϫ/Ϫ males to generate 25-50% LPLϪ/Ϫ pups. As previously described, LPLϪ/Ϫ pups were rescued on the day of birth by intramuscular (IM) administration of recombinant adenovirus-LPL S447X vector (1 ϫ 10 8 plaque forming units [pfu] per mouse) and genotypes were determined by PCR-based genotyping (Ross et al., 2004) . LPLϪ/Ϫ mice and ϩ/Ϫ and ϩ/ϩ littermates were maintained on a C57BL/6J background and raised on regular rodent diet with free access to water. All procedures involving animals were performed in accordance with protocols from the CCAC (Canadian Council for Animal Care) and the UBC Animal Care Committee. 
Fat tolerance test
LPLϪ/Ϫ mice treated with AAV1-LPL S447X or AAV-GFP, or untreated LPLϩ/Ϫ or LPLϩ/ϩ (wild-type) mice, were injected intravenously (IV; tail vein) with 250 l of a 2:1 dilution of 30% Intralipid (Fresenius Kabi, Uppsala, Sweden; 3000 kcal/L, per 100 ml: 30 g purified soybean oil, 1.2 g egg phospholipid, 1.67 g glycerol anhydrous). Small blood samples were subsequently taken at indicated time points from the saphenous vein, for the determination of TG and FFA.
Analyses of blood
Fasted (4 hr) blood plasma samples were collected before vector administration and then at regular intervals for the duration of the experiment after vector administration. Postheparin plasma was collected 20 min after intraperitoneal (IP) injection of 1000 U/kg heparin. Plasma was assayed for LPL activity, LPL protein, and plasma lipids as previously described (Ross et al., 2004 ; mouse monoclonal antibody [mAb] 5D2 a kind gift from Dr. J. Brunzell, University of Washington, Seattle, WA). Muscle myopathy was determined by assaying plasma creatine phosphokinase (CPK) levels (Vitros CK Slide, Ortho Clinical Diagnostics, Rochester, NY).
Analyses of tissues
After 12 and 58 weeks, animals were sacrificed by cervical dislocation. A whole-body perfusion with PBS was performed and tissues were harvested and frozen on dry ice or fixed in 4% formalin. Tissues were homogenized and assayed for LPL activity and LPL protein by enzyme-linked immunosorbent assay (ELISA), and tissue lipids were extracted for quantification of tissue lipids (TG, total cholesterol [TC] , FFA) (Bligh and Dyer, 1959) . Tissues were also sectioned to 10-15 m and examined for hLPL protein and green fluorescent protein (GFP) localization in situ by hLPL immunohistochemistry using anti-LPL mAb AM4 or by direct observation of GFP fluorescence, respectively. Fixed tissues were processed and stained using standard histological methods for hematoxylin and eosin (H&E) periodic acid Schiff (PAS), oil red O (ORO), and MassonTrichrome (MT) stains.
Statistical analysis
Results are given as mean Ϯ standard deviation (SD). Statistical significance was tested using two-tailed Student's t test to compare two groups, or analysis of variance (ANOVA) with Tukey's multiple comparison test when comparing more than two groups.
RESULTS
AAV1-mediated expression of functional LPL was confirmed in cultured C2C12 cells (3 ϫ 10 5 ) infected with AAV1-LPL S447X (2.6 ϫ 10 9 gc) in the presence of wild-type adenovirus. At 72-hr postinfection, fresh media containing heparin was added, and 24 hr later LPL activity was detected in cell lysate (2.3 Ϯ 0.3 mU/ml) and media (21.6 Ϯ 2.9 mU/ml). In addition, the expression of functional LPL was confirmed in cultured primary human skeletal muscle cells (unpublished data). Adult male LPLϪ/Ϫ mice, 10-16 months of age, were generated as described previously (Ross et al., 2004) . These mice express very low levels of residual LPL activity (5.5% of normal) and hLPL protein, derived from the adenoviral transfer of LPL S447X at birth as part of the procedure to rescue these mice from neonatal death. Consequently, adult LPLϪ/Ϫ mice displayed lipemic (milky) plasma, characterized by a 220-fold increase of fasting plasma TG levels, a 9-fold increased total cholesterol (TC), a 4-fold increased FFA, and a 90% reduction of normal HDL-C levels (Table 1) . 5 per group) by IM injection in 36 sites. A control group was injected IM in 36 sites with PBS. LPLϪ/Ϫ mice treated with a high dose of AAV1-LPL S447X showed a significant increase in postheparin plasma LPL activity, up to 33% of normal murine levels (week 2-10 average 131 Ϯ 40 mU/ml; p Ͻ 0.001 versus controls and low dose). A 10-fold lower dose resulted in a modest increase in plasma LPL activity, to 9% of normal murine levels (N.S.) (Fig. 1B) .
Dose-dependent expression of hLPL in plasma after IM administration of AAV1-LPL S447X
Analysis of human LPL protein levels in plasma after treatment of LPLϪ/Ϫ mice with a high dose of AAV1-LPL S447X showed a 12-fold increase over PBS-treated controls, to 1188 Ϯ 540 ng/ml (p Ͻ 0.01 versus controls and low dose). For reference, this level of hLPL protein is equivalent to 61% of the level observed in postheparin plasma of human S447X carriers (Ross et al., 2004) . LPLϪ/Ϫ mice treated with a low dose of AAV1-LPL S447X showed a significant 2-fold increase in plasma hLPL protein levels over PBS controls (week 2-10 average, 202 Ϯ 32 ng/ml versus 101 Ϯ 40 ng/ml; p Ͻ 0.01) (Fig.  1A) .
Dose-dependent correction of dyslipidemia after IM administration of AAV1-LPL S447X
Remarkably, visible hyperlipidemia in plasma observed in LPLϪ/Ϫ mice was cleared within 1 week after administration of the high dose of AAV1-LPL S447X (Fig. 2) . Concomitant with these results, dramatic reductions of total plasma TG and TC ( plasma TG level was reduced by 98.0% from pretreatment levels (from 99.0 Ϯ 21.4 to 2.0 Ϯ 0.2 mmol/L; p Ͻ 0.001 versus controls) and plasma TC was reduced by 92%. A 10-fold lower dose resulted in a slower clearance of plasma lipids, and complete resolution was not achieved (Fig. 2) . Nevertheless, an average 73.1% reduction of plasma TG (to 26.6 Ϯ 2.3 mmol/L; p Ͻ 0.001 versus controls and high dose), and a 76.0% reduction of plasma TC (p Ͻ 0.001 versus controls and high dose) was observed at 4 weeks posttransfer ( Fig. 3A and 3B ). Treatment of LPLϪ/Ϫ mice with the high dose of AAV1-LPL S447X fully normalized FFA levels (p Ͻ 0.001) (Fig. 3C) . However, FFA levels in LPLϪ/Ϫ mice injected with a 10-fold lower dose remained elevated. The reduction in plasma TG was accompanied by an equally rapid improvement of plasma HDL-C levels, which were significantly increased in LPLϪ/Ϫ mice treated with a high dose of AAV1-LPL S447X (from 0.2 Ϯ 0.1 to 1.1 Ϯ 0.1 mmol/L; p Ͻ 0.001), to 61% of wild-type levels (Fig. 3D) . A 10-fold lower dose increased HDL-C levels 2.5-fold (to 0.41 Ϯ 0.03 mmol/L; p Ͻ 0.001), to 24% of wild-type levels.
These results demonstrate that AAV1-mediated expression of human LPL S447X in the skeletal muscle of LPLϪ/Ϫ mice resulted in a dose-dependent normalization of the dyslipidemia that is associated with LPL deficiency.
Dose-dependent expression of hLPL in muscle after IM administration of AAV1-LPL S447X
At 12 weeks posttreatment, the mice were sacrificed for the analysis of LPL protein and activity within the injected gastrocnemius and adductor muscles, as well as in the liver, heart, and adipose tissue. LPL protein and activity was readily detected in the injected muscles (similar results were observed for gastrocnemius and adductor muscles, so the representative gastrocnemius results are shown), but not in liver, heart, or adipose of LPLϪ/Ϫ mice treated with the high or low dose of AAV1-LPL S447X ( Table 2 ), suggesting that muscle-derived transgenic LPL, although secreted, remained locally bound within the injected tissue. LPLϪ/Ϫ mice treated with the high dose of AAV1-LPL S447X showed a 9-fold higher local LPL activity in the gastrocnemius muscle compared to mice treated with a 10-fold lower dose (33.7 Ϯ 15.4 versus 3.9 Ϯ 2.5 mU/mg protein; p Ͻ 0.01) and both groups showed significantly higher tissue LPL activity compared to PBS-treated LPLϪ/Ϫ mice (0.6 Ϯ 0.4 mU/mg protein; p Ͻ 0.05). Compared to LPL activity in muscle of wild-type mice (3.1 Ϯ 1 mU/mg protein), the low viral dose of AAV1-LPL S447X induced expression of normal levels of tissue LPL activity, whereas administration of a 10-fold higher dose resulted in a local tissue LPL activity that exceeded wild-type levels 11-fold (p Ͻ 0.01).
Quantification of hLPL protein in the gastrocnemius muscle showed a 14-fold higher level of hLPL protein in LPLϪ/Ϫ mice treated with the high viral dose, compared to mice treated with the 10-fold lower dose (225 Ϯ 195 versus 15.7 Ϯ 11.1 ng/mg protein; p Ͻ 0.05), and both groups showed significantly higher levels of muscle hLPL protein than PBS-treated controls (Ϫ0.3 Ϯ 0.7 ng/mg protein; p Ͻ 0.05). In situ staining of the gastrocnemius muscle with antibodies specific for hLPL also indicated a dose-dependent expression of LPL protein (Fig. 1C) . 
Improved muscle histology following IM administration of AAV1-LPL S447X
The effect of murine LPL deficiency on particular tissues has thus far not been addressed. We chose to assess muscle histology of treated and untreated LPLϪ/Ϫ mice because it was the site of injection. Cross-sections of the injected gastrocnemius and adductor muscles from all treatment groups isolated 12 weeks after gene transfer were stained with H&E for general histology, with PAS to stain for glycogen content, with a Masson-Trichrome stain for collagen content, and ORO for lipid content (Fig. 4) . Unexpectedly, untreated LPLϪ/Ϫ mice showed a disorganized muscle morphology, and the presence of large intermyofibrillar lesions rich in collagen and neutral lipid droplets (ORO-positive material). Large amounts of PASpositive material indicated accumulation of glycogen within individual myofibers. Remarkably, treatment with the high dose of AAV1-LPL S447X restored muscle histology within the pe- 
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riod of 12 weeks after treatment, with an intermediate improvement using a 10-fold lower dose.
Reduced skeletal muscle lipid content with IM administration of AAV1-LPL S447X
The gastrocnemius muscle was also assayed for tissue lipid content 12 weeks after treatment. Compared to wild-type controls, untreated LPLϪ/Ϫ mice showed a more than 3-fold elevated muscle TG and FFA content (p Ͻ 0.001), and a trend toward increased TC content (2.1-fold) ( Table 3) . Correction of muscle histology in LPLϪ/Ϫ mice treated with 8 ϫ 10 12 gc/kg was accompanied by a significant 50% reduction of TG content of the gastrocnemius muscle (p Ͻ 0.001). Trends toward reduction of tissue TC and FFA content were observed. A 10-fold lower dose, however, did not significantly affect muscle lipid content.
Influence of an increased dose of AAV1-LPL S447X per injection site
To determine if a reduced number of vector injection sites affected LPL synthesis or the correction of dyslipidemia, the high dose of AAV1-LPL S447X was also administered to LPLϪ/Ϫ mice in 4 injection sites, thereby increasing the dose per site 9-fold. In plasma, the 4-site regimen produced similar levels of LPL activity and LPL protein and resulted in a similar correction of plasma lipids compared to 36 injection sites (data not shown). In muscle, local LPL protein expression was proportionately increased 10-fold (p Ͻ 0.01) and LPL activity was increased 3-fold (p Ͻ 0.001) ( Table 2) , while tissue TG content was normalized (Table 3) .
Long-term hLPL expression and correction of dyslipidemia (more than 1 year) in LPLϪ/Ϫ mice after IM administration of AAV1-LPL S447X
To address the duration of transgene expression, and its effect on plasma lipids, a separate group of 3 month-old LPLϪ/Ϫ mice were injected IM with a similar high dose (8 ϫ 10 12 gc/kg) of AAV1-LPL S447X in 36 sites and followed for over a year. AAV1-GFP was used as a control. Expression of LPL protein and activity was detected for the duration of the experiment, although there was a decline in both LPL protein and activity ( Fig. 5A and 5B) beyond the 12-week time point. This decline was evident in both Ad-derived residual LPL expression (as determined in the AAV1-GFP-treated group), as well as in AAV1-derived LPL expression. Nevertheless, after treatment TG levels in LPLϪ/Ϫ mice were reduced by 97% to an average 1.8 Ϯ 0.2 mmol/L for the duration of the experiment (Fig.  5C ). In contrast, AAV1-GFP treated mice showed a 64% increase in TG levels over the same period of time. HDL-C levels were increased 3.3-fold for the duration of the experiment (Fig. 5D) . The collective changes in plasma lipids were further exemplified by complete resolution of visible lipemia lasting over 1 year after gene transfer (Fig. 5E ).
Efficient handling of an intravenous fat load after IM treatment of LPLϪ/Ϫ mice with AAV1-LPL S447X
To assess whether this gene therapy strategy was sufficiently effective to influence the postprandial response to a high-fat load, LPLϪ/Ϫ mice were injected IV with Intralipid, 8 months after transfer of 8 ϫ 10 12 gc/kg of AAV1-LPL S447X . Control wild-type mice demonstrated a marked increase of plasma TG levels within 1 min after injection, and a peak TG level of 60-70 mmol/L (Fig. 6) . TG levels returned to near baseline levels within 2 hr (clearance rate, 21.7 Ϯ 6 mmol/L per hour). Control LPLϩ/Ϫ mice demonstrated a similar clearance rate (21.6 Ϯ 2.2 mmol/L per hr) indicating that mice with only a single copy of LPL, and reduced tissue LPL activity (Table 2) , possess full capacity to hydrolyze plasma TG. LPLϪ/Ϫ mice, on the other hand, displayed a much slower TG clearance rate compared to wild-type and LPLϩ/Ϫ controls (5.7 Ϯ 0.9 mmol/L per hour; p Ͻ 0.05). Remarkably, this impaired clearance was fully corrected in LPLϪ/Ϫ mice treated with AAV1-LPL S447X , showing a rapid initial clearance of plasma TG similar to that of heterozygous and wild type mice (clearance rate: 19.4 Ϯ 9.5 mmol/L per hour). Assessment of FFA levels after Intralipid injection mirrored the effects on TG levels (data not shown).
DISCUSSION
Intramuscular administration of AAV1-LPL S447X to adult LPLϪ/Ϫ mice resulted in a long-term, dose-dependent correction of gross dyslipidemia, including a dramatic reduction in plasma TG, TC, and FFA, and a remarkable recovery of plasma HDL-C. Treated LPLϪ/Ϫ mice also handled a high fat-load normally. Analysis of injected muscle tissue showed improvement of muscle morphology and tissue lipid content when compared to nontreated LPLϪ/Ϫ mice. The effects on plasma lipids lasted for more than 1 year after a single administration of the vector. These results unequivocally demonstrate that long-term near complete correction of a lipid disorder using gene therapy is feasible.
Dose-dependent expression of therapeutic levels of LPL protein and activity was observed in plasma. The amount of LPL expressed in muscle correlated with the viral dose. With the viral dose per site varying 10-fold, amounting to 6.7 ϫ 10 8 (low 
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FIG. 5.
Long-term correction of lipoprotein lipase (LPL) deficiency in LPLϪ/Ϫ mice with AAV1-LPL S447X . LPLϪ/Ϫ mice treated with 8 ϫ 10 12 genome copies per kilogram (gc/kg) of AAV1-LPL S447X showed significantly increased plasma hLPL protein (A) and LPL activity (B) for a year compared to LPLϪ/Ϫ treated with an equivalent dose of AAV1-GFP control vector. The levels of LPL in plasma reached a peak by week 12, after which LPL levels slowly declined. Changes in plasma triglyceride (TG; C) and high-density lipoprotein cholesterol (HDL-C; D) occurred largely within 2 weeks after administration of AAV1-LPL S447X , and remained at similar, near-normal, levels for the duration of the 1 year experiment. Treated LPLϪ/Ϫ mice showed concomitant clearing of visible plasma hyperlipidemia to a normal appearance (E). p values versus Ϫ/Ϫ controls *p Ͻ 0.05, **p Ͻ 0.01, ***p Ͻ 0.001. Wild-type and ϩ/Ϫ mice showed similar rapid triglyceride (TG) clearance rates while LPLϪ/Ϫ mice treated with a control AAV1-GFP vector showed a 4-fold slower clearance rate. LPLϪ/Ϫ mice treated with AAV1-LPL S447X showed a rapid initial clearance of plasma TG similar to that of wild-type and ϩ/Ϫ mice. Results are an average of n ϭ 3 per group Ϯ standard deviation (SD), and are expressed as a percentage of the peak in TG levels observed for each animal after administration of Intralipid.
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dose, 36 sites), 6.7 ϫ 10 9 (high dose, 36 sites), and 6.3 ϫ 10 10 gc per site (high dose, 4 sites), the contribution to postheparin plasma LPL levels per injected muscle area increased accordingly to 3.0, 30.4, and 206.7 ng/ml. Thus, at these viral doses, the protein production machinery of the skeletal muscle did not become a limiting factor. Therapeutic levels of gene expression were achieved with a viral dose between 8 ϫ 10 11 and 8 ϫ 10 12 gc/kg. Even though LPL activity only reached 33% of that of normal mice, this was sufficient to fully correct dyslipidemia. This was also borne out in LPLϩ/Ϫ mice, where despite a loss of tissue LPL activity (Table 2) an efficient clearance of a high fat load was observed (Fig. 6 ). In fact, a level of LPL activity less than 10% of normal achieved with the lower dose of AAV1-LPL S447X was sufficient to reduce TG by more than 70%. This would suggest that, similar to other inherited biochemical disorders, a fraction of normal LPL activity may be sufficient to be therapeutically effective.
AAV1-mediated expression of LPL S447X was induced in less than 1 week at a dose of 8 ϫ 10 12 gc/kg, and long-lasting (for more than 1 year). Twelve weeks after injection, however, LPL expression slowly declined (Fig. 5) . This decline was also observed for the residual LPL expression (Ad-derived) in AAV1-GFP-treated LPLϪ/Ϫ mice, and may in part represent muscle tissue turnover. Skeletal muscle shows a constant demand for new myonuclei as precursors for myofibers, in response to growth or damage. A recent estimate of turnover of myonuclei in rat muscle suggests that 1-2% of such cells are turned over each week (Schmalbruch and Lewis, 2000; Zammit and Beauchamp, 2001) , which would suggest that after 1 year 65% of a given (transduced) cell population has been replaced. Alternatively, transgene expression under control of the cytomegalovirus (CMV) promoter may be affected by inflammatory signals. Transient levels of serum amyloid A, a general marker of inflammation, are observed shortly after gene transfer (unpublished results). We did not observe an immune response against LPL. This is likely related to the fact that these mice have been made tolerant at birth by the treatment with Ad-LPL S447X . However, anti-AAV1 antibodies were detected in similar studies, using a similar dose (unpublished results). Importantly, despite the decline, plasma lipid levels remained corrected, indicating that therapeutic LPL levels were produced for more than 1 year.
AAV1-mediated expression of LPL S447X resulted in the immediate correction of hyperlipidemia associated with (murine) LPL deficiency: both TG and TC were restored to near-normal levels, exemplified by the complete resolution of visible hyperlipidemia. Hydrolysis of TG from CM/VLDL particles, through LPL activity in muscle, generates cholesterol-rich remnants that are efficiently cleared by the liver. Hence the reduction in plasma TG was accompanied by a comparable decrease in plasma TC. As previously reported, LPLϪ/Ϫ mice also display low levels of HDL-C (Strauss et al., 2001; Ross et al., 2004) , which mimics the situation in LPL-deficient patients, who also present with low levels of plasma HDL-C (Bijvoet et al., 1996) in addition to excessive plasma TG. The reduction in plasma TG observed in treated LPLϪ/Ϫ mice was accompanied by a remarkable improvement in plasma HDL-C levels, in line with LPL-mediated lipolysis of TG providing constituents for the maturation of HDL particles (Bijvoet et al., 1996; Strauss et al., 2001) . We now show that by restoring muscle LPL expression we can correct both the high TG and low HDL-C phenotype that is associated with LPL deficiency. It has not previously been possible to address the effects of murine LPL deficiency on particular tissues because LPLϪ/Ϫ mice do not normally survive the neonatal period. Using gene therapy with LPL S447X we have overcome this issue and established an adult model of LPL deficiency for further analyses. Interestingly, adult LPLϪ/Ϫ mice display a disturbed muscle morphology, and deposition of large amounts glycogen and lipid (TG, FFA, and TC). Excessive glycogen storage in muscle is also observed in patients with various forms of glycogen storage disease. Glycogen breakdown in muscle is highly regulated, particularly by increased levels of FFA in response to, for example, a change from carbohydrate to fat metabolism. Increased muscle FFA content has been linked to myopathy (Levak-Frank et al., 1995) . Remarkably, expression of LPL S447X in the muscle of LPLϪ/Ϫ mice resulted in normalization of muscle histology within 12 weeks. The high dose of AAV1-LPL S447X (8 ϫ 10 12 gc/kg), distributed over 36 different muscle groups, showed a morphology that was indistinguishable from wild-type controls. The treatment also improved tissue lipid content, and more so with higher local LPL expression (the 4-site regimen). This is an important observation, as over-expression of LPL in muscle by 5.5-fold to 24.4-fold in transgenic mice has been shown to cause severe myopathy (Levak-Frank et al., 1995) , attributed to the accumulation of FFA in muscle. Our study differs from these studies in two respects: (1) we expressed a variant form of human LPL, hLPL S447X , within the context of LPL deficiency, with an already greatly disturbed muscle morphology and FFA content; (2) overexpression of hLPL S447X in muscle, even at levels 11-fold to 24-fold over wild-type levels, resulted in the reduction of muscle FFA content in corresponding samples. Our study shows, therefore, that local overexpression of hLPL S447X within the context of LPL deficiency reduces muscle lipid and glycogen accumulation and improves muscle histology. We suspect that in the state of LPL deficiency, the prolonged exposure to high plasma TG (increased 100-fold) and FFA (increased 4-fold) eventually results in accumulation of these lipids in tissues. Plasma FFA may be increased through non-LPL-mediated hydrolysis of accumulated plasma TG (i.e., by hepatic lipase) resulting in increased muscle FFA uptake and lipid accumulation.
As a general marker of muscle trauma, we also monitored plasma creatine phosphokinase (CPK) levels in these mice. After treatment with AAV1-LPL S447X , however, CPK levels remained normal at all time points (weeks 1 to 12) (data not shown). Taken together, we did not observe any signs of local toxicity in muscle of treated mice in response to the AAV infection, transgene expression, or overexpression of LPL in particular. Rather, treatment of LPL-deficient mice resulted in significant improvement of muscle histology.
The beneficial effects of AAV1-LPL S447X treatment on plasma lipids in LPLϪ/Ϫ mice provide an initial example of long-term near correction of hypertriglyceridemia using gene therapy. Although the effect of AAV1-LPL S447X cannot be accurately estimated in humans at this time, it is clear that even a moderately similar effect would significantly improve the health and quality of life of LPL-deficient patients. This study indicates that LPL gene therapy for human LPL deficiency may be feasible, for a number of reasons: (1) even partial correction of LPL activity (Ͻ10% of normal) has profound effects on plasma lipid levels; (2) transduction of a limited muscle mass (as observed with the 4-site regimen) is sufficient to clear the entire plasma TG pool; (3) the muscle is very amenable to dosedependent AAV1-mediated LPL expression, and high local viral doses are tolerated. Finally, treatment provided resistance to a high TG load. This is particularly relevant in human LPL deficiency, where a consistent adherence to a low-fat diet (Ͻ15% of caloric intake [Brunzell and Deeb, 2001] ) is required to prevent recurrent pancreatitis. LPL gene transfer may thus provide considerable improvement of the quality of life, possibly allowing a less-stringent diet.
In summary, treatment of LPLϪ/Ϫ mice with AAV1-LPL S447X results in long-term expression of therapeutic levels of LPL, and correction of the high TG and low HDL-C phenotype associated with murine LPL deficiency.
